



Myocarditis Associated with Mesalazine: A Case Report

Abdulmecit Afşin¹, Ali Yiğit², Murat Yağmur³

¹İnönü University School of Medicine, Department of Cardiology, Malatya, Turkey

²İnönü University School of Medicine,, Department of Internal Diseases, Malatya, Turkey

³Malatya State Hospital, Internal Diseases Clinic, Malatya, Turkey

Abstract

Acute myocarditis is a life-threatening inflammatory disease of the heart muscle. It usually occurs after a viral infection and it is often asymptomatic. Mesalazine is commonly used for the treatment of inflammatory bowel disease. Mesalazine rarely causes acute myocarditis, but the exact mechanism is unclear. A 32-year-old female patient using mesalazine with a diagnosis inflammatory bowel disease was admitted to the emergency department with shortness of breath. The patient showed signs of acute decompensated heart failure. Bedside echocardiography examination showed a reduced left ventricular systolic function. The patient was followed with a diagnosis of fulminant myocarditis and mechanical ventilation and inotropic support was started. The patient has dramatically improved after stopping treatment of mesalazine. Myocarditis due to any drug use should be taken into consideration in patients receiving mesalazine therapy.

Key Words: Mesalazine; Myocarditis; Crohn's Disease.

Mesalazin ile İlişkili Miyokardit: Olgu Sunumu

Özet

Akut miyokardit hayatı tehdit edebilen kalp kasının inflamatuvar bir hastalığıdır. Genellikle viral enfeksiyon sonrası gelişir ve sıklıkla asemptomatik seyrederek. İnflamatuvar barsak hastalıklarında mesalazin yaygın olarak kullanılmaktadır. Mekanizması tam olarak bilinmemekle birlikte mesalazinin akut miyokardite neden olduğu bilinmektedir. İnflamatuvar barsak hastalığı tanısıyla mesalazin kullanan 32 yaşındaki bayan hasta, nefes darlığı şikayetiyle acil servise başvurdu. Hastada akut dekompanse kalp yetmezliği bulguları mevcuttu. Yatak başı ekokardiyografide azalmış sol ventrikül sistolik fonksiyonları izlendi. Hasta fulminan miyokardit tanısıyla takip edildi, mekanik ventilator ve inotropik destek tedavisi verildi. Hasta mesalazin tedavisi stoplandıktan sonra dramatik bir şekilde iyileşti. Mesalazin tedavisi alan hastalarda ilaç ile ilişkili miyokardit tanısı göz önünde bulundurulması gerekmektedir.

Anahtar Kelimeler: Mesalazin; Miyokardit; Crohn Hastalığı.

INTRODUCTION

Myocarditis is defined as an inflammatory infiltration of the myocardium associated with necrosis or degeneration or both. Although most myocarditis cases are self-limiting, severe cardiac failure may develop, which may rapidly lead to death. Myocarditis may be caused by infections, chemicals, physical agents, toxins, or rheumatological diseases. In addition, myocarditis may be secondary to the use of several drugs as some drugs are already known to cause hypersensitivity myocarditis (1). We present a case of myocarditis arising due to mesalazine use in a patient with Crohn's disease.

CASE REPORT

A 32-year-old female was admitted to emergency service with shortness of breath, she was intubated due to increased hypoxemia and respiratory distress. When the patient was consulted with cardiology department, it was revealed that the patient had no history of cardiovascular disease or any associated risk factors and she had been using mesalazine for 6 months for Crohn's disease. Her physical examination revealed tachycardia, third heart sound, decreased respiratory sounds,

bilateral jugular venous distension, and slight peripheral edema. Electrocardiographic examination revealed sinus tachycardia, nonspecific ST segment, and T wave changes. There were leukocytosis (16×10^3), troponin-I levels [5.2 ng/ml, normal reference values 0-1 ng/ml], inflammatory markers such as erythrocyte sedimentation rate [70, normal reference value <10], and C reactive protein [6.3 mg/L, normal reference value 0-0.3 mg/L]. The bedside echocardiography examination showed a decreased ejection fraction (EF) of 20% and the left ventricle was globally hypokinetic (Figure 1a).

Diffuse bilateral pleural effusion and cardiomegaly were detected on the computerized tomography of the thorax (Figure 2). The treatment was maintained for cardiac failure and the patient was supported with positive inotropic agents. Her mesalazine treatment was withdrawn due to possible side effect of cardiac failure of mesalazine. The case was evaluated as fulminant myocarditis and followed up with mechanic ventilation support for 6 days after which the patient was successfully extubated. Viral, bacterial, and inflammatory causes of acute fulminant myocarditis were excluded according to serological markers (Chlamydia, Mycoplasma pneumoniae, Epstein-Barr virus and Cytomegalovirus), anti-nuclear antibody (ANA), anti-

smooth muscle antibody (ASMA), anti-double-stranded deoxyribonucleic acid (Anti-dsDNA), and rheumatoid factor (RF). The stool culture, which was positive for vancomycin resistant enterococcus at the time of hospitalization, was considered as nosocomial infection (or contamination). She had an apparent clinical recovery by the tenth day of the hospitalization. Transthoracic echocardiography was repeated and EF was detected to be 60% (Figure 1b). Posteroanterior chest radiograph revealed a normal cardiothoracic index with no pleural effusion and clear cardiophrenic and costophrenic angles (Figure 3). We did not detect ischemia on myocardial perfusion imaging and ischemic cardiomyopathy was, thus, excluded. The patient was discharged with maintenance therapy.




Figure 1a. Increased left ventricle diastolic diameter on parasternal short axis.
Figure 1b. Normal ejection fraction on apical 4-chamber view.




Figure 2. Bilateral massive pleural effusion, increased cardiothoracic index.




Figure 3. Normal cardiothoracic index; no pleural effusion and clear angles on chest radiograph.

DISCUSSION

Clinical manifestations of myocarditis may indicate a course ranging from asymptomatic period to fulminant myocarditis. Patients usually present with acute decompensated heart failure in fulminant myocarditis.

Our patient had no history of any cardiac diseases and she was in a state of acute decompensated heart failure. Complaint of dyspnea had started 5 days ago. The bedside echocardiography showed a decreased EF of 20%. The rapid clinical and laboratory improvement after the withdrawal of mesalazine gave rise to the idea of fulminant myocarditis due to mesalazine use.

The case was considered as myocarditis due to mesalazine use. Heart diseases such as pericarditis (70%) and myocarditis (10%) may accompany the inflammatory bowel disease as extraintestinal manifestations (2). Mesalazine is commonly used for the treatment of inflammatory bowel diseases. Its side effects include fever, rash, renal damage, liver dysfunction, myocarditis, nephropathy, and pancreatitis. The relationship between mesalazine and myocarditis is not clear (3). Kounis et al. explained the possible mechanism of the inhibition of cyclooxygenase-1 enzyme (COX-1) and, thus, overproduction of leukotriens which further promote an initiation of hypersensitivity reaction via eosinophil secreting factor induced by proinflammatory signals and, eventually, causing myocarditis. The relationship between mesalazine and myocarditis is thought to be due to hypersensitivity reaction rather than cytotoxic effects (2, 3). Previous studies showed eosinophilic infiltration of the myocardium in mesalazine associated myocarditis in biopsy (4). Although patients with a hypersensitivity disease may develop arteritis, acute myocardial infarction rarely occurs (5). In several studies, development of giant cell myocarditis was shown histologically in the course of autoimmune disorders such as Crohn's disease (6). Mesalazine associated eosinophilic myocarditis or giant cell myocarditis was considered in our case. Because a provocative test with etiologic agent could lead fatal damage, it was not performed (2-4). Similarly, we did not perform an endomyocardial biopsy because the patient refused to consent to the biopsy.

In conclusion, drug induced myocarditis is a rarely observed condition. A careful history is of great importance. In a case presenting with chest pain and shortening of breath and receiving mesalazine treatment for inflammatory bowel disease, drug induced myocarditis should be taken into account. Making prior notification to patients receiving mesalazine for inflammatory bowel disease may prevent delay in reaching proper diagnosis.

REFERENCES

1. Kounis NG, Zavras GM, Soufras GD, Kitrou MP. Hypersensitivity myocarditis. *Ann Allergy* 1989;62:71-4.

2. Kristensen KS, Hoegholm A, Bohr L, Friis S. Fatal myocarditis associated with mesalazin. *Lancet* 1990;335:605.
3. Kounis GN, Kouni SA, Chiladakis JA, Kounis NG. Comment: Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis and the kounis syndrome. *Ann Pharmacoter* 2009;43:393-94.
4. Stelts S, Taylor MH, Nappi J, Van Bakel AB. Mesalamine associated hypersensitivity myocarditis ulcerative colitis. *Ann Pharmacoter* 2008;42:904-05.
5. Galiuto L, Enriquez S, Reeder GS, Tazelaar HD, Li JT, Miller FA, et al. Eosinophilic myocarditis, manifesting as myocardial infarction: early diagnosis, and succesful treatment. *Mayo clin proc* 1997;72:603-10.
6. Nash CL, Panaccione R, Sutherland LR, Meddings JB. Giant cell myocarditis in a patient with Crohn disease treated with etanercept-a tumour necrosis factor-alfa antagonist. *Can J Gastroenterol* 2001;15:607-11.

Received/Başvuru: 03.08.2014, Accepted/Kabul: 13.10.2014

Correspondence/İletişim

Abdulmecit AFSİN
İnönü Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı,
MALATYA, TÜRKİYE
E-mail: abdulmecitafsin@mynet.com



For citing/Atıf için

Afsin A, Yigit A, Yagmur M. Myocarditis associated with mesalazine: a case report. *J Turgut Ozal Med Cent* 2015;22:184-6 DOI:10.7247/jtomc.2014.2325